Treatment and outcome
The patient was started on hydroxyurea, allopurinol, and hydration.
Imatinib 400mg p.o/day was begun after cytoreduction.
She received conservative care for the hematoma accumulation and was
discharged with appointments to the surgery and hematology clinics. In
two weeks, she has significantly improved.
Conclusion
It is important to keep in mind that unexplained soft tissue hematoma
can be an initial manifestation of chronic myelogenous leukemia.
However, the exact cause of the Morel Lavallee lesion is not yet known,
platelet dysfunction, acquired Von Willebrand disease, and acquired
Glanzmann’s thrombasthenia are the most likely causes. supportive care
and tyrosine kinase inhibitors are the main mode of management. Surgical
interventions can be considered based on indications.